Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like Phoenix Molecular Designs Appoints Leading Oncology Expert As Chief Scientific Officer July 16, 2017 Oncolytics Biotech, Adlai Nortye Forge $86.6M Reolysin Deal November 16, 2017 Bay Area's CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects With $200 Million Upfront in Deal Totaling $5 Billion March 19, 2017
Bay Area's CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects With $200 Million Upfront in Deal Totaling $5 Billion March 19, 2017
